Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$40m beat estimates by a substantial 30 ...

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...

Mersana Therapeutics has a one year low of $0.46 and a one year high of $6.28. The business’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $1.55.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue ...

March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.

On Tuesday, 11 March 2025, Mersana Therapeutics (NASDAQ ... And I think even in their public communications, they were looking more towards frontline therapy. And one of the things that they ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$40m beat estimates by a substantial 30% ...